Sec. 878. Country-of-origin disclosure requirements for generic drugs purchased by the Department of Defense
42 words·~1 min read·
/bill/119/s/2296/es/section-878A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
The Department of Defense may not procure for resale any generic drug unless the seller of such generic drug discloses the country the generic drug was manufactured in and the country of origin for all active pharmaceutical ingredients and key starting materials.